Health In Tech Swings to Q2 Loss, Reaffirms $45-50M Revenue Guidance
HIT sits 20% above its 52-week low of $0.85.
Summary
Health In Tech posted a Q2 2026 net loss of $2.5 million on revenue of $8.1 million, down from a profit of $0.6 million a year ago. Full-year revenue guidance of $45-50 million was reaffirmed.
Key Events · Earnings and Guidance · HIT
-
Q2 Loss vs Prior-Year Profit
Net loss of $2.5 million, or $(0.04) per diluted share, compared to net income of $0.6 million, or $0.01 per share, in Q2 2025.
-
Revenue Declines 13%
Q2 2026 revenue was $8.1 million, down from $9.3 million in Q2 2025, driven by a 39% drop in underwriting modeling revenue.
-
Operating Cash Burn
Operating activities used $2.9 million in cash during Q2 2026, leaving $6.5 million in cash and equivalents as of June 30, 2026.
-
Guidance Reaffirmed
Full-year 2026 revenue guidance of $45 million to $50 million was reaffirmed, supported by $32.3 million in contracted revenue and a $66.3 million pipeline.
Analysis · HIT · Finance
The quarter's swing to a $2.5 million net loss from a $0.6 million profit a year earlier reflects a 13% revenue decline and a 32% jump in operating expenses. Operating cash burn reached $2.9 million, leaving $6.5 million in cash. Management reaffirmed full-year revenue guidance of $45-50 million, backed by $32.3 million in contracted revenue and a $66.3 million pipeline, but the near-term profitability deterioration and cash burn dominate the story.
At the time of this filing, HIT was trading at $1.02 on NASDAQ in the Finance sector, with a market capitalization of approximately $69.5M. The 52-week trading range was $0.85 to $4.02. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.